tarceva

Introduction to Tarceva

Tarceva is a prescription medication primarily used to treat certain types of cancer. It is specifically designed for patients with non-small cell lung cancer (NSCLC) and pancreatic cancer. As a targeted therapy, Tarceva works by interfering with the growth and spread of cancer cells in the body. This medication is typically prescribed for patients whose cancer has progressed despite previous treatments. Available in the form of tablets, Tarceva provides a non-invasive option for patients undergoing cancer treatment, making it a convenient choice for many. It is important to follow your healthcare provider's instructions when taking Tarceva to ensure its effectiveness and minimize potential side effects.

Composition of Tarceva

The active ingredient in Tarceva is Erlotinib, which is present in a 100mg dosage per tablet. Erlotinib is a type of medication known as an epidermal growth factor receptor (EGFR) inhibitor. It works by blocking the activity of a certain protein that is responsible for the growth and spread of cancer cells. By targeting and inhibiting this protein, Erlotinib helps to slow down or stop the proliferation of cancerous cells, thereby aiding in the management of cancer. This targeted approach allows for more precise treatment with potentially fewer side effects compared to traditional chemotherapy.

Uses for Tarceva

• Treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC).
• Used in combination with gemcitabine for the treatment of locally advanced, unresectable, or metastatic pancreatic cancer.

Side Effects of Tarceva

• Rash and acne-like skin reactions
• Diarrhea
• Loss of appetite
• Fatigue
• Breathing difficulties
• Cough
• Nausea and vomiting
• Eye irritation

Precautions for Tarceva

Before starting Tarceva, inform your healthcare provider about any allergies, medical conditions, or medications you are currently taking. It is crucial to avoid smoking while on Tarceva, as it can reduce the effectiveness of the medication. Pregnant or breastfeeding women should not use Tarceva due to potential harm to the baby. Regular monitoring of liver function and other blood tests may be required during treatment. Patients should also protect their skin from sun exposure, as Tarceva can increase sensitivity to sunlight.

Conclusion

Tarceva, with its active ingredient Erlotinib, offers a targeted approach to cancer treatment, particularly for non-small cell lung cancer and pancreatic cancer. By inhibiting cancer cell growth, it provides an effective option for patients whose cancer has progressed. While generally well-tolerated, it is important to be aware of potential side effects and take necessary precautions. Always follow your healthcare provider's guidance to ensure the best possible outcome while using Tarceva.